Filtered By:
Cancer: Acute Lymphoblastic Leukemia
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 59 results found since Jan 2013.
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809. Online ahead of print.ABSTRACTAlthough a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of patients do not respond to conventional chemotherapy and experience disease relapse. A major effort to improve the cure rates by treatment intensification would result in an undesirable increase in treatment-related toxicity and mortality, raising the need to identify novel therapeutic approaches. High-throughput (HTP) drug screening enables the profiling of patients' responses in vitro and allows the repurposing of compounds currently ...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Athanasios Oikonomou Luigia Valsecchi Manuel Quadri Titus Watrin Katerina Scharov Simona Procopio Jia-Wey Tu Melina Vogt Angela Maria Savino Daniela Silvestri Maria Grazia Valsecchi Andrea Biondi Arndt Borkhardt Sanil Bhatia Giovanni Cazzaniga Grazia Fazi Source Type: research
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
ConclusionIn adults with newly diagnosed Ph + ALL, first-line treatment with ponatinib was associated with better outcomes than first-line treatment with imatinib.
Source: Advances in Therapy - May 19, 2023 Category: Drugs & Pharmacology Source Type: research
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era
Curr Res Transl Med. 2023 Apr 23;71(2):103392. doi: 10.1016/j.retram.2023.103392. Online ahead of print.ABSTRACTBefore the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was dismal. The TKI combination with induction regimens has greatly improved the long-term outcome of Ph+ ALL, specifically ponatinib a most potent TKI in combination with HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) chemotherapy has demonstrated 5 years overall survival up to 75%. Historically, allogeneic hematopoietic stem c...
Source: Cell Research - April 30, 2023 Category: Cytology Authors: Talha Badar Hassan Alkhateeb Mahmoud Aljurf Mohamed A Kharfan-Dabaja Source Type: research
Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL
Blood Adv. 2023 Mar 10:bloodadvances.2021006881. doi: 10.1182/bloodadvances.2021006881. Online ahead of print.ABSTRACTGlucocorticoids (GCs) are a cornerstone of acute lymphoblastic leukemia (ALL) therapy. While mutations in NR3C1, which encodes the GC receptor (GR), and other genes involved in GC signaling occur at relapse, additional mechanisms of adaptive GC resistance are uncertain. We transplanted and treated ten primary mouse T-lineage acute lymphoblastic leukemias (T-ALLs) initiated by retroviral insertional mutagenesis with the GC dexamethasone (DEX). Multiple, distinct relapsed clones from one such leukemia (T-ALL ...
Source: Adv Data - March 10, 2023 Category: Epidemiology Authors: Anya Levinson Karensa Tjoa Benjamin J Huang Lauren K Meyer Mi-Ok Kim Samuel W Brady Jinghui Zhang Kevin M Shannon Anica Wandler Source Type: research
Vincristine and Dexamethasone Pulses in Addition to Maintenance Therapy Among Pediatric Acute Lymphoblastic Leukemia(GD-ALL-2008): an Open-label, Multicentre, Randomized, Phase III Clinical Trial
This article is protected by copyright. All rights reserved.PMID:36877527 | DOI:10.1002/ajh.26910
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Kun-Yin Qiu Jia-Yi Wang Li-Bin Huang Chang-Gang Li Lu-Hong Xu Ri-Yang Liu Hui-Qin Chen Yong-Sheng Ruan Zi-Jun Zhen Chi-Kong Li Jian-Pei Fang Source Type: research
Combination therapy of a PSEN1-selective gamma-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia
Haematologica. 2023 Jan 26. doi: 10.3324/haematol.2022.282144. Online ahead of print.ABSTRACTNot available.PMID:36700404 | DOI:10.3324/haematol.2022.282144
Source: Haematologica - January 26, 2023 Category: Hematology Authors: Charlien Vandersmissen Cristina Prieto Olga Gielen Kris Jacobs David Nittner Johan Maertens Heidi Segers Jan Cools Source Type: research
B and T cell acute lymphoblastic leukemia evade chemotherapy at distinct sites in the bone marrow
Haematologica. 2022 Nov 3. doi: 10.3324/haematol.2021.280451. Online ahead of print.ABSTRACTPersistence of residual disease after induction chemotherapy is a strong predictor of relapse in acute lymphoblastic leukemia (ALL). The bone marrow microenvironment may support treatment escape. Using 3D fluorescence imaging of 10 primary ALL xenografts we identify sites of predilection in the bone marrow for resistance to induction with dexamethasone, vincristine and doxorubicin. We detect B-cell precursor ALL cells predominantly in the perisinusoidal space at early engraftment and after chemotherapy. The spatial distribution of T...
Source: Haematologica - November 3, 2022 Category: Hematology Authors: Malwine J Barz Lena Behrmann Dana ëlle Capron Gabriele Zuchtriegel Fabio D Steffen Leo Kunz Yang Zhang Iria Jimenez Vermeerbergen Blerim Marovca Moritz Kirschmann Antonia Zech C ésar Nombela-Arrieta Urs Ziegler Timm Schroeder Beat Bornhauser Jean-Pierre Source Type: research
